<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02871570</url>
  </required_header>
  <id_info>
    <org_study_id>B5201006</org_study_id>
    <nct_id>NCT02871570</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function</brief_title>
  <official_title>A Phase 1, Non-randomized, Open-label, Parallel-group Single-dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Intravenous Rivipansel (Pf-06460031) In Subjects With Moderate Hepatic Impairment And In Healthy Subjects With Normal Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlycoMimetics Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlycoMimetics Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of hepatic impairment on rivipansel PK
      and safety.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Post-baseline Clinically Significant Findings in Physical Examinations</measure>
    <time_frame>Day 5</time_frame>
    <description>A full physical examination was performed for each participant, and it included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes and gastrointestinal, musculoskeletal, and neurological systems. Clinical significance of laboratory findings was determined by the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Day 1 to follow-up visit (28-31 days after administration of study medication on Day 1)</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device, regardless of its causal relationship with study treatment. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; was life-threatening (immediate risk of death); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events between administration of study medication and up to follow-up visit (28-31 days after administration) that were absent before treatment or that worsened after treatment. AEs included both serious and non-serious AEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Electrocardiogram (ECG) Data Meeting Pre-defined Summarization Criteria</measure>
    <time_frame>Day 5</time_frame>
    <description>Maximum absolute values and increases from baseline were summarized for PR interval (time from the beginning of P wave to the start of QRS complex, corresponding to the end of atrial depolarization and onset of ventricular depolarization), QRS duration (time from Q wave to the end of S wave, corresponding to ventricle depolarization), and QTcF interval (time from the beginning of Q wave to the end of T wave corresponding to electrical systole corrected for heart rate using Fridericia's formula). Number of participants with ECG findings meeting the following criteria is presented: (1) PR interval &gt;=300 msec; (2) QRS duration &gt;=200 msec; (3) QTcF interval: 450 to &lt;480 msec; (4) QTcF interval: 480 to &lt;500 msec; (5) QTcF interval &gt;=500 msec; (6) PR interval percent increase from baseline &gt;=25/50 percent; (7) QRS duration percent increase from baseline &gt;=50 percent; (8) QTcF interval increase from baseline: 30 to &lt;60 msec; (9) QTcF interval increase from baseline &gt;=60 msec.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Vital Signs Data Meeting Pre-defined Summarization Criteria</measure>
    <time_frame>Day 1 to Day 5</time_frame>
    <description>Absolute values and changes from baseline (increase and decrease) were summarized for supine diastolic blood pressure (DBP), supine systolic blood pressure (SBP), and supine pulse rate. Number of participants with vital signs findings meeting the following criteria is presented: (1) supine DBP &lt;50 millimeters of mercury (mm Hg); (2) supine DBP &gt;90 mm Hg; (3) supine SBP &lt;90 mm Hg; (4) supine SBP &gt;140 mm Hg (for normal hepatic function group); (5) supine SBP &gt;160 mm Hg (for moderate hepatic impairment group); (6) supine pulse rate &lt; 40 beats per minute (bpm); (7) supine pulse rate &gt;120 bpm; (8) supine DBP increase from baseline &gt;=20 mm Hg; (9) supine SBP increase from baseline &gt;=30 mmHg; (10) supine DBP decrease from baseline &gt;=20 mm Hg; (11) supine SBP decrease from baseline &gt;=30 mm Hg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)</measure>
    <time_frame>Day 5</time_frame>
    <description>Laboratory tests included: hematology (hemoglobin, hematocrit, red and white blood cell count, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes, prothrombin time/international normalized ratio), chemistry (blood urea nitrogen/urea and creatinine, fasting glucose, calcium, sodium, potassium, chloride, total carbon dioxide, aspartate and alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid, albumin, total protein), urinalysis (pH, qualitative glucose, protein, and blood, ketones, nitrites, leukocyte esterase, urobilinogen, urine bilirubin, and microscopy), and other tests (follicle stimulating hormone, urine drug test and serologic tests on human immunodeficiency virus-1 antibody, Hepatitis B surface antigen and hepatitis C antibody). Abnormality was determined by the investigator using widely accepted criteria in clinical practice.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Rivipansel</measure>
    <time_frame>Pre-dose, 0.33, 1, 3, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose on Day 1</time_frame>
    <description>AUCinf was calculated as AUClast + (Clast*/kel), where Clast* was the predicted plasma concentration at the last quantifiable time point estimated from the log linear regression analysis, kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Clearance From Plasma (CL) of Rivipansel</measure>
    <time_frame>Pre-dose, 0.33, 1, 3, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose on Day 1</time_frame>
    <description>CL of rivipansel was calculated as dose/AUCinf, where AUCinf referred to the area under the plasma concentration-time profile from time 0 extrapolated to the infinite time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Rivipansel</measure>
    <time_frame>Pre-dose, 0.33, 1, 3, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose on Day 1</time_frame>
    <description>Area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration (AUClast) of rivipansel was determined using a linear/log trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of Rivipansel</measure>
    <time_frame>Pre-dose, 0.33, 1, 3, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-Life of Rivipansel</measure>
    <time_frame>Pre-dose, 0.33, 1, 3, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose on Day 1</time_frame>
    <description>Terminal half-life of rivipansel was calculated as loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) of Rivipansel</measure>
    <time_frame>Pre-dose, 0.33, 1, 3, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose on Day 1</time_frame>
    <description>Vss of rivipansel was calculated as CL*MRT, where MRT was the mean residence time and CL was the clearance from plasma.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time for Maximum Observed Concentration (Tmax) of Rivipansel</measure>
    <time_frame>Pre-dose, 0.33, 1, 3, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose on Day 1</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Moderate Hepatic Impairment</condition>
  <condition>Normal Hepatic Function</condition>
  <arm_group>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of IV Rivipansel over 20 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Hepatic Function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of IV Rivipansel over 20 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivipansel</intervention_name>
    <description>A single dose of IV Rivipansel over 20 minutes</description>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <arm_group_label>Normal Hepatic Function</arm_group_label>
    <other_name>GMI-1070</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects of non-childbearing potential or male subjects

               -  Body Mass Index (BMI) of 17.5 to 40.0 kg/m2

               -  Normal Hepatic function for the healthy subjects

               -  Stable Hepatic Impairment for the subjects with moderate hepatic impairment

        Exclusion Criteria:

          -  Treatment with an investigational drug within 30 days of the dose of study medication

          -  Pregnant females, breastfeeding female subjects and male subjects with partners
             currently pregnant

          -  Use of herbal supplements in the 28 days prior to the dose of study medication

          -  Blood donation (excluding plasma donation) of approximately 1 pint or more within 56
             days prior to study medication

          -  A positive urine drug screen for illicit drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orlando Clincial Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2016</study_first_posted>
  <results_first_submitted>February 14, 2018</results_first_submitted>
  <results_first_submitted_qc>February 14, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 28, 2018</results_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic Impairment</keyword>
  <keyword>Rivipansel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 27, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT02871570/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 2, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT02871570/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Moderate Hepatic Impairment Group</title>
          <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with moderate hepatic impairment.</description>
        </group>
        <group group_id="P2">
          <title>Normal Hepatic Function Group</title>
          <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with normal hepatic function.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline analysis population included all participants who received study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Moderate Hepatic Impairment Group</title>
          <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with moderate hepatic impairment.</description>
        </group>
        <group group_id="B2">
          <title>Normal Hepatic Function Group</title>
          <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with normal hepatic function.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.00" spread="3.85"/>
                    <measurement group_id="B2" value="58.75" spread="4.43"/>
                    <measurement group_id="B3" value="58.38" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Post-baseline Clinically Significant Findings in Physical Examinations</title>
        <description>A full physical examination was performed for each participant, and it included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes and gastrointestinal, musculoskeletal, and neurological systems. Clinical significance of laboratory findings was determined by the investigator.</description>
        <time_frame>Day 5</time_frame>
        <population>Safety analysis set included all participants who received study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment Group</title>
            <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with moderate hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Normal Hepatic Function Group</title>
            <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with normal hepatic function.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Post-baseline Clinically Significant Findings in Physical Examinations</title>
          <description>A full physical examination was performed for each participant, and it included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes and gastrointestinal, musculoskeletal, and neurological systems. Clinical significance of laboratory findings was determined by the investigator.</description>
          <population>Safety analysis set included all participants who received study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device, regardless of its causal relationship with study treatment. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; was life-threatening (immediate risk of death); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events between administration of study medication and up to follow-up visit (28-31 days after administration) that were absent before treatment or that worsened after treatment. AEs included both serious and non-serious AEs.</description>
        <time_frame>Day 1 to follow-up visit (28-31 days after administration of study medication on Day 1)</time_frame>
        <population>Safety analysis set included all participants who received study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment Group</title>
            <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with moderate hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Normal Hepatic Function Group</title>
            <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with normal hepatic function.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device, regardless of its causal relationship with study treatment. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; was life-threatening (immediate risk of death); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events between administration of study medication and up to follow-up visit (28-31 days after administration) that were absent before treatment or that worsened after treatment. AEs included both serious and non-serious AEs.</description>
          <population>Safety analysis set included all participants who received study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Electrocardiogram (ECG) Data Meeting Pre-defined Summarization Criteria</title>
        <description>Maximum absolute values and increases from baseline were summarized for PR interval (time from the beginning of P wave to the start of QRS complex, corresponding to the end of atrial depolarization and onset of ventricular depolarization), QRS duration (time from Q wave to the end of S wave, corresponding to ventricle depolarization), and QTcF interval (time from the beginning of Q wave to the end of T wave corresponding to electrical systole corrected for heart rate using Fridericia's formula). Number of participants with ECG findings meeting the following criteria is presented: (1) PR interval &gt;=300 msec; (2) QRS duration &gt;=200 msec; (3) QTcF interval: 450 to &lt;480 msec; (4) QTcF interval: 480 to &lt;500 msec; (5) QTcF interval &gt;=500 msec; (6) PR interval percent increase from baseline &gt;=25/50 percent; (7) QRS duration percent increase from baseline &gt;=50 percent; (8) QTcF interval increase from baseline: 30 to &lt;60 msec; (9) QTcF interval increase from baseline &gt;=60 msec.</description>
        <time_frame>Day 5</time_frame>
        <population>Safety analysis set included all participants who received study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment Group</title>
            <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with moderate hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Normal Hepatic Function Group</title>
            <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with normal hepatic function.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Electrocardiogram (ECG) Data Meeting Pre-defined Summarization Criteria</title>
          <description>Maximum absolute values and increases from baseline were summarized for PR interval (time from the beginning of P wave to the start of QRS complex, corresponding to the end of atrial depolarization and onset of ventricular depolarization), QRS duration (time from Q wave to the end of S wave, corresponding to ventricle depolarization), and QTcF interval (time from the beginning of Q wave to the end of T wave corresponding to electrical systole corrected for heart rate using Fridericia's formula). Number of participants with ECG findings meeting the following criteria is presented: (1) PR interval &gt;=300 msec; (2) QRS duration &gt;=200 msec; (3) QTcF interval: 450 to &lt;480 msec; (4) QTcF interval: 480 to &lt;500 msec; (5) QTcF interval &gt;=500 msec; (6) PR interval percent increase from baseline &gt;=25/50 percent; (7) QRS duration percent increase from baseline &gt;=50 percent; (8) QTcF interval increase from baseline: 30 to &lt;60 msec; (9) QTcF interval increase from baseline &gt;=60 msec.</description>
          <population>Safety analysis set included all participants who received study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR interval &gt;=300 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration &gt;=200 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval: 450 to &lt;480 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval: 480 to &lt;500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval &gt;=500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval increase from baseline &gt;=25/50 percent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration increase from baseline &gt;=50 percent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF increase from baseline: 30 to &lt;60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval increase from baseline &gt;=60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vital Signs Data Meeting Pre-defined Summarization Criteria</title>
        <description>Absolute values and changes from baseline (increase and decrease) were summarized for supine diastolic blood pressure (DBP), supine systolic blood pressure (SBP), and supine pulse rate. Number of participants with vital signs findings meeting the following criteria is presented: (1) supine DBP &lt;50 millimeters of mercury (mm Hg); (2) supine DBP &gt;90 mm Hg; (3) supine SBP &lt;90 mm Hg; (4) supine SBP &gt;140 mm Hg (for normal hepatic function group); (5) supine SBP &gt;160 mm Hg (for moderate hepatic impairment group); (6) supine pulse rate &lt; 40 beats per minute (bpm); (7) supine pulse rate &gt;120 bpm; (8) supine DBP increase from baseline &gt;=20 mm Hg; (9) supine SBP increase from baseline &gt;=30 mmHg; (10) supine DBP decrease from baseline &gt;=20 mm Hg; (11) supine SBP decrease from baseline &gt;=30 mm Hg.</description>
        <time_frame>Day 1 to Day 5</time_frame>
        <population>Safety analysis set included all participants who received study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment Group</title>
            <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with moderate hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Normal Hepatic Function Group</title>
            <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with normal hepatic function.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Signs Data Meeting Pre-defined Summarization Criteria</title>
          <description>Absolute values and changes from baseline (increase and decrease) were summarized for supine diastolic blood pressure (DBP), supine systolic blood pressure (SBP), and supine pulse rate. Number of participants with vital signs findings meeting the following criteria is presented: (1) supine DBP &lt;50 millimeters of mercury (mm Hg); (2) supine DBP &gt;90 mm Hg; (3) supine SBP &lt;90 mm Hg; (4) supine SBP &gt;140 mm Hg (for normal hepatic function group); (5) supine SBP &gt;160 mm Hg (for moderate hepatic impairment group); (6) supine pulse rate &lt; 40 beats per minute (bpm); (7) supine pulse rate &gt;120 bpm; (8) supine DBP increase from baseline &gt;=20 mm Hg; (9) supine SBP increase from baseline &gt;=30 mmHg; (10) supine DBP decrease from baseline &gt;=20 mm Hg; (11) supine SBP decrease from baseline &gt;=30 mm Hg.</description>
          <population>Safety analysis set included all participants who received study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>supine DBP &lt;50 mm Hg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>supine DBP &gt;90 mm Hg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>supine SBP &lt;90 mm Hg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>supine SBP &gt;140 mm Hg (normal function group)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>supine SBP &gt;160 mm Hg (moderate impairment group)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>supine pulse rate &lt;40 bpm</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>supine pulse rate &gt;120 bpm</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>supine DBP increase from baseline &gt;=20 mm Hg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>supine SBP increase from baseline &gt;=30 mmHg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>supine DBP decrease from baseline &gt;=20 mm Hg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>supine SBP decrease from baseline &gt;=30 mm Hg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)</title>
        <description>Laboratory tests included: hematology (hemoglobin, hematocrit, red and white blood cell count, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes, prothrombin time/international normalized ratio), chemistry (blood urea nitrogen/urea and creatinine, fasting glucose, calcium, sodium, potassium, chloride, total carbon dioxide, aspartate and alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid, albumin, total protein), urinalysis (pH, qualitative glucose, protein, and blood, ketones, nitrites, leukocyte esterase, urobilinogen, urine bilirubin, and microscopy), and other tests (follicle stimulating hormone, urine drug test and serologic tests on human immunodeficiency virus-1 antibody, Hepatitis B surface antigen and hepatitis C antibody). Abnormality was determined by the investigator using widely accepted criteria in clinical practice.</description>
        <time_frame>Day 5</time_frame>
        <population>Safety analysis set included all participants who received study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment Group</title>
            <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with moderate hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Normal Hepatic Function Group</title>
            <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with normal hepatic function.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)</title>
          <description>Laboratory tests included: hematology (hemoglobin, hematocrit, red and white blood cell count, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes, prothrombin time/international normalized ratio), chemistry (blood urea nitrogen/urea and creatinine, fasting glucose, calcium, sodium, potassium, chloride, total carbon dioxide, aspartate and alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid, albumin, total protein), urinalysis (pH, qualitative glucose, protein, and blood, ketones, nitrites, leukocyte esterase, urobilinogen, urine bilirubin, and microscopy), and other tests (follicle stimulating hormone, urine drug test and serologic tests on human immunodeficiency virus-1 antibody, Hepatitis B surface antigen and hepatitis C antibody). Abnormality was determined by the investigator using widely accepted criteria in clinical practice.</description>
          <population>Safety analysis set included all participants who received study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Rivipansel</title>
        <description>AUCinf was calculated as AUClast + (Clast*/kel), where Clast* was the predicted plasma concentration at the last quantifiable time point estimated from the log linear regression analysis, kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.</description>
        <time_frame>Pre-dose, 0.33, 1, 3, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose on Day 1</time_frame>
        <population>The pharmacokinetic (PK) parameter analysis population included all participants treated who had at least one of the PK parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment Group</title>
            <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with moderate hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Normal Hepatic Function Group</title>
            <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with normal hepatic function.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Rivipansel</title>
          <description>AUCinf was calculated as AUClast + (Clast*/kel), where Clast* was the predicted plasma concentration at the last quantifiable time point estimated from the log linear regression analysis, kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.</description>
          <population>The pharmacokinetic (PK) parameter analysis population included all participants treated who had at least one of the PK parameters of primary interest.</population>
          <units>hour*microgram/milliliter (hr*mcg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="599.7" spread="25"/>
                    <measurement group_id="O2" value="770.0" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>ratio</param_type>
            <param_value>0.7789</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6514</ci_lower_limit>
            <ci_upper_limit>0.9313</ci_upper_limit>
            <estimate_desc>Moderate hepatic impairment group represents the numerator, and normal hepatic function group represents the denominator.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Rivipansel</title>
        <description>Area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration (AUClast) of rivipansel was determined using a linear/log trapezoidal method.</description>
        <time_frame>Pre-dose, 0.33, 1, 3, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose on Day 1</time_frame>
        <population>The PK parameter analysis population included all participants treated who had at least one of the PK parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment Group</title>
            <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with moderate hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Normal Hepatic Function Group</title>
            <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with normal hepatic function.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Rivipansel</title>
          <description>Area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration (AUClast) of rivipansel was determined using a linear/log trapezoidal method.</description>
          <population>The PK parameter analysis population included all participants treated who had at least one of the PK parameters of primary interest.</population>
          <units>hr*mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="593.8" spread="26"/>
                    <measurement group_id="O2" value="763.7" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>ratio</param_type>
            <param_value>0.7776</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6493</ci_lower_limit>
            <ci_upper_limit>0.9311</ci_upper_limit>
            <estimate_desc>Moderate hepatic impairment group represents the numerator, and normal hepatic function group represents the denominator.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Clearance From Plasma (CL) of Rivipansel</title>
        <description>CL of rivipansel was calculated as dose/AUCinf, where AUCinf referred to the area under the plasma concentration-time profile from time 0 extrapolated to the infinite time.</description>
        <time_frame>Pre-dose, 0.33, 1, 3, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose on Day 1</time_frame>
        <population>The PK parameter analysis population included all participants treated who had at least one of the PK parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment Group</title>
            <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with moderate hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Normal Hepatic Function Group</title>
            <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with normal hepatic function.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Clearance From Plasma (CL) of Rivipansel</title>
          <description>CL of rivipansel was calculated as dose/AUCinf, where AUCinf referred to the area under the plasma concentration-time profile from time 0 extrapolated to the infinite time.</description>
          <population>The PK parameter analysis population included all participants treated who had at least one of the PK parameters of primary interest.</population>
          <units>liter/hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.401" spread="26"/>
                    <measurement group_id="O2" value="1.091" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>ratio</param_type>
            <param_value>1.2844</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0732</ci_lower_limit>
            <ci_upper_limit>1.5372</ci_upper_limit>
            <estimate_desc>Moderate hepatic impairment group represents the numerator, and normal hepatic function group represents the denominator.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Concentration (Cmax) of Rivipansel</title>
        <time_frame>Pre-dose, 0.33, 1, 3, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose on Day 1</time_frame>
        <population>The PK concentration population included all participants treated who had at least 1 PK concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment Group</title>
            <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with moderate hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Normal Hepatic Function Group</title>
            <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with normal hepatic function.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) of Rivipansel</title>
          <population>The PK concentration population included all participants treated who had at least 1 PK concentration.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.91" spread="38"/>
                    <measurement group_id="O2" value="98.06" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>ratio</param_type>
            <param_value>0.7945</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5955</ci_lower_limit>
            <ci_upper_limit>1.0599</ci_upper_limit>
            <estimate_desc>Moderate hepatic impairment group represents the numerator, and normal hepatic function group represents the denominator.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-Life of Rivipansel</title>
        <description>Terminal half-life of rivipansel was calculated as loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration time curve.</description>
        <time_frame>Pre-dose, 0.33, 1, 3, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose on Day 1</time_frame>
        <population>The PK parameter analysis population included all participants treated who had at least one of the PK parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment Group</title>
            <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with moderate hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Normal Hepatic Function Group</title>
            <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with normal hepatic function.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-Life of Rivipansel</title>
          <description>Terminal half-life of rivipansel was calculated as loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration time curve.</description>
          <population>The PK parameter analysis population included all participants treated who had at least one of the PK parameters of primary interest.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.653" spread="0.964"/>
                    <measurement group_id="O2" value="7.805" spread="0.923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution at Steady State (Vss) of Rivipansel</title>
        <description>Vss of rivipansel was calculated as CL*MRT, where MRT was the mean residence time and CL was the clearance from plasma.</description>
        <time_frame>Pre-dose, 0.33, 1, 3, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose on Day 1</time_frame>
        <population>The PK parameter analysis population included all participants treated who had at least one of the PK parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment Group</title>
            <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with moderate hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Normal Hepatic Function Group</title>
            <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with normal hepatic function.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution at Steady State (Vss) of Rivipansel</title>
          <description>Vss of rivipansel was calculated as CL*MRT, where MRT was the mean residence time and CL was the clearance from plasma.</description>
          <population>The PK parameter analysis population included all participants treated who had at least one of the PK parameters of primary interest.</population>
          <units>liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.08" spread="29"/>
                    <measurement group_id="O2" value="11.20" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time for Maximum Observed Concentration (Tmax) of Rivipansel</title>
        <time_frame>Pre-dose, 0.33, 1, 3, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose on Day 1</time_frame>
        <population>The PK parameter analysis population included all participants treated who had at least one of the PK parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment Group</title>
            <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with moderate hepatic impairment.</description>
          </group>
          <group group_id="O2">
            <title>Normal Hepatic Function Group</title>
            <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with normal hepatic function.</description>
          </group>
        </group_list>
        <measure>
          <title>Time for Maximum Observed Concentration (Tmax) of Rivipansel</title>
          <population>The PK parameter analysis population included all participants treated who had at least one of the PK parameters of primary interest.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.667" lower_limit="0.667" upper_limit="3.33"/>
                    <measurement group_id="O2" value="0.667" lower_limit="0.667" upper_limit="0.667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 to follow-up visit (28-31 days after administration of study medication on Day 1)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Moderate Hepatic Impairment Group</title>
          <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with moderate hepatic impairment.</description>
        </group>
        <group group_id="E2">
          <title>Normal Hepatic Function Group</title>
          <description>A single dose of rivipansel 840 mg was administered intravenously (IV) to a group of participants with normal hepatic function.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

